RUA Life Sciences Plc - Company Profile
Powered by 
All the data and insights you need on RUA Life Sciences Plc in one report.
$295
- Save hours of research time and resources with
our up-to-date RUA Life Sciences Plc Strategy Report
- Understand RUA Life Sciences Plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
RUA Life Sciences Plc (RUA Life Sciences), formerly AorTech International Plc is a medical device company that focuses on the exploitation of the world's long-term implantable biostable polymers and technologies used in the development of medical devices. The company through its subsidiaries develops and manufactures medical devices, large bore vascular grafts, cardiovascular and soft tissue patches, and tri-leaflet polymeric heart valves. It offers Elast-Eon biostable polyurethanes used in medical devices for long-term implantation; ECSil, biomedical polymers used in spinal discs, cardiac pacing leads, and orthopedics; and Elast-Eon reaction injection molding (RIM) products. The company also offers to design and contract manufacturing services to medical device and biotech companies. RUA Life Sciences is headquartered in Ayrshire, Scotland, the UK.
Headquarters
United Kingdom
Address
2 Drummond Crescent, Irvine, Ayrshire, Scotland, KA115AN
Website
rualifesciences.com
Telephone
44 1294 317073
No of Employees
40
Industry
Medical Equipment
Ticker Symbol & Exchange
RUA (LON)
Revenue (2023)
$2.7M
34.1%
(2023 vs 2022)
EPS
XYZ
Net Income (2023)
XYZ
3.1%
(2023 vs 2022)
Market Cap*
$8.0M
Net Profit Margin (2023)
XYZ
27.7%
(2023 vs 2022)
* As of and is in US$
RUA Life Sciences Plc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| - | - | - |
| RUA Biomaterials: | Designing | ECSil |
| Elast Eon | Contract Manufacturing Services | Elast-Eon |
| XYZ | ||
| XYZ | ||
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In January, the company entered into a partnership with Corcym SRL to bring RUA's range of large-bore vascular grafts to market. |
| 2020 | Financing Agreements | In December, the company announced to raise EUR 6.0 million in an open offer. |
| 2020 | Corporate Changes/Expansions | In June, the company changed its name from AorTech International Plc to RUA Life Sciences Plc. |
Competitor Comparison
| Key Parameters | RUA Life Sciences Plc | Sientra Inc | B. Braun Medical Ltd | Dow Silicones Corp | Medicor Ltd. |
|---|---|---|---|---|---|
| Headquarters | United Kingdom | United States of America | United Kingdom | United States of America | United States of America |
| City | Ayrshire | Irvine | Sheffield | Midland | Las Vegas |
| State/Province | Scotland | California | England | Michigan | Nevada |
| No. of Employees | 40 | 304 | - | 37,000 | 410 |
| Entity Type | Public | Public | Private | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| William Brown | Chairman | Executive Board | 2012 | - |
| Lachlan Smith | Chief Financial Officer; Director | Executive Board | 2022 | - |
| John McKenna | Director - Clinical Marketing | Executive Board | 2016 | - |
| Caroline Stretton | Chief Operating Officer | Senior Management | 2021 | - |
| Geoffrey Berg | Director | Non Executive Board | 2018 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer